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Consequence of the tumor-associated conversion
to cyclin D1b
Michael A Augello1,2, Lisa D Berman-Booty1,2, Richard Carr 3rd2,3, Akihiro Yoshida4,5, Jeffry L Dean1,2,
Matthew J Schiewer1,2, Felix Y Feng6,7,8, Scott A Tomlins6,8,9, Erhe Gao10, Walter J Koch10,11,
Jeffrey L Benovic2,3, John Alan Diehl4,5 & Karen E Knudsen1,2,12,13,*

Abstract

Introduction

Clinical evidence suggests that cyclin D1b, a variant of cyclin D1,
is associated with tumor progression and poor outcome.
However, the underlying molecular basis was unknown. Here,
novel models were created to generate a genetic switch from
cyclin D1 to cyclin D1b. Extensive analyses uncovered overlapping but non-redundant functions of cyclin D1b compared to
cyclin D1 on developmental phenotypes, and illustrated the
importance of the transcriptional regulatory functions of cyclin
D1b in vivo. Data obtained identify cyclin D1b as an oncogene,
wherein cyclin D1b expression under the endogenous promoter
induced cellular transformation and further cooperated with
known oncogenes to promote tumor growth in vivo. Further
molecular interrogation uncovered unexpected links between
cyclin D1b and the DNA damage/PARP1 regulatory networks,
which could be exploited to suppress cyclin D1b-driven tumors.
Collectively, these data are the first to define the consequence of
cyclin D1b expression on normal cellular function, present
evidence for cyclin D1b as an oncogene, and provide pre-clinical
evidence of effective methods to thwart growth of cells dependent upon this oncogenic variant.

D-Type cyclins link mitogenic stimuli to the cell cycle machinery
and have well-established roles in cancer (Musgrove et al, 2011).
Accumulation of cyclin D1 is enhanced in response to pro-proliferative
signals and engages the cell cycle machinery by direct binding and
activation of CDK4/6 complexes (Musgrove et al, 2011; Malumbres
& Barbacid, 2009). cyclin D1/CDK4/6 subsequently phosphorylates
key substrates (including the retinoblastoma tumor suppressor, RB)
which induces progression from G1 to S phase (Malumbres &
Barbacid, 2009). While these cell cycle regulatory functions of
cyclin D1 have been well described and are conserved across most
cell and tissue types (Musgrove et al, 2011; Malumbres & Barbacid,
2009), additional, largely CDK4/6-independent functions of cyclin
D1 are known to be essential for distinct biological activities. The
most well-described function of cyclin D1 outside cell cycle control
is the ability to act as a transcriptional co-regulator (Bienvenu et al,
2010; Musgrove et al, 2011). The transcriptional regulatory activities of cyclin D1 have been shown in multiple systems to modulate
pathways critical for both development and tumorigenesis (Bienvenu
et al, 2010; Comstock et al, 2011, 2013; Musgrove et al, 2011;
McMahon et al, 1999; Fu et al, 2005). Further insight was gleaned
from analyses of the cyclin D1 interactome, which uncovered a large
network of transcriptional regulators in complex with cyclin D1
(Bienvenu et al, 2010). Accordingly, parallel studies identified an
essential domain of cyclin D1 that was responsible for steroid receptor interaction, termed the repressor domain (Petre-Draviam et al,
2003, 2005; Burd et al, 2005), which is paramount for modulation
of steroid receptor action and associated downstream biology
(Comstock et al, 2011, 2013; Zwijsen et al, 1997; Knudsen et al,
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1999; Schiewer et al, 2009). Thus, the biological functions of cyclin
D1 appear to be manifest through regulation of both cell cycle
progression and selected gene expression networks.
Given the influential functions of cyclin D1 on cell proliferation
and signaling, cyclin D1 expression is stringently regulated. In
cancer cells, however, deregulation of cyclin D1 is common and is
often associated with development and progression of human malignancies (Musgrove et al, 2011). Evidence from human tumors
uncovered multiple mechanisms through which cyclin D1 expression is deregulated, most of which involve alterations of the CCND1
locus itself (Musgrove et al, 2011). These include the following: (1)
amplification of the CCND1 gene (observed frequently in breast,
pancreatic, skin, lung, and head and neck cancers) (Arnold & Papanikolaou, 2005; Garcea et al, 2005; Thomas et al, 2005; Li et al,
2006; Gautschi et al, 2007), (2) translocation of the CCND1 locus to
IGH enhancer elements (seen in nearly all cases of mantle cell
lymphoma) (Bosch et al, 1994; Bigoni et al, 1996), and (3) mutations in the sequences encoding the cyclin D1 PEST domain (which
occur in esophageal cancers) (Benzeno et al, 2006). While these
genetic aberrations are associated with altered cyclin D1 expression,
the clinical significance has proven to be highly variable. In mantle
cell lymphoma (MCL), deregulation of the CCND1 locus is prognostic and has been implicated as a driver of disease onset, but is
dispensable for disease progression (Bertoni et al, 2006; Gladden
et al, 2006). Among other malignancies with cyclin D1 locus alterations, there is little evidence of association with tumor progression.
For example, no consistent association of cyclin D1 amplification
was found with response to therapeutic challenge in patients with
hormone receptor-positive breast cancer (Lundgren et al, 2012;
Rudas et al, 2008). Furthermore, mutations within the coding
region of cyclin D1, found in cases of esophageal and endometrial
cancer (Moreno-Bueno et al, 2003; Benzeno et al, 2006), have yet
to be associated with clinical markers of disease progression,
together suggesting that the observed oncogenic functions of cyclin
D1 involve additional mechanisms of deregulation. Consistent with
this concept, emerging clinical evidence suggests that alternative
splicing of cyclin D1 transcript (cyclin D1a) to the shorter isoform
cyclin D1b occurs frequently in human malignancy (Augello et al,
2014; Musgrove et al, 2011; Wang et al, 2008; Comstock et al,
2009), and appears to be a major mechanism though which cyclin
D1 exerts its oncogenic activity.
Cyclin D1b represents a putatively neoplastic-specific isoform of
cyclin D1, which arises as a failure to splice at the exon 4/intron 4
boundary of the cyclin D1 pre-mRNA (Solomon et al, 2003;
Knudsen, 2006). This results in the incorporation of an early stop
codon and loss of C-terminal-encoded sequences important for the
transcriptional regulatory functions and stability of full-length
cyclin D1 (termed cyclin D1a). Consequently, cyclin D1b harbors a
unique 33 amino acid C-terminus, which represents a ‘gain-offunction’ cyclin D1 variant (Augello et al, 2014; Lu et al, 2003; Solomon
et al, 2003). This concept is supported by clinical evidence demonstrating that cyclin D1b is induced in lymphoma, esophageal, breast,
lung, and prostate cancer (Augello et al, 2014; Lu et al, 2003;
Carrere et al, 2005; Li et al, 2008; Comstock et al, 2009; Millar et al,
2009). Furthermore, in contrast to cyclin D1a, cyclin D1b expression
is associated with tumor progression and therapeutic failure in
breast (Wang et al, 2008) and prostate cancer (Augello et al, 2014;
Comstock et al, 2009), and is an independent predictor of poor

ª 2015 The Authors

EMBO Molecular Medicine

Consequence of the conversion to cyclin D1b

prognosis and survival in small-cell lung cancer (Li et al, 2008).
Although these findings suggest that cyclin D1b represents an oncogenic isoform of cyclin D1, the molecular impact of the endogenous
switch to cyclin D1b, as occurs in tumors, remains unclear.
Given the established clinical importance of cyclin D1b induction, novel models harboring a genetic switch from cyclin D1a to
cyclin D1b were generated herein and uncovered the effects of the
switch to cyclin D1b expression on developmental and cellular
transformation phenotypes. First, extensive in vivo analyses uncovered overlapping but non-redundant functions with that of cyclin
D1a, providing the first evidence of divergent action of this isoform
on normal cellular processes. Furthermore, in vitro models provided
evidence to support the role of cyclin D1b as an oncogene, fostering
transformation of primary cells and cooperating with established
oncogenes to drive tumor formation in vivo. Importantly, cyclin
D1b-mediated transformation was associated with enhanced presence of markers of DNA damage, providing mechanistic insight into
the oncogenic action of this isoform. This is of potential clinical relevance, as cyclin D1b-transformed cells were hypersensitized to cell
cycle arrest and senescence through combined genotoxic insult,
providing preclinical insight into mechanisms that can be utilized to
target cyclin D1b-expressing tumors. This study thus established a
first-in-field model of the switch to cyclin D1b, identified unique
roles for this isoform, and put forth novel strategies for treating
cyclin D1b-positive tumors.

Results
Humanization of the Ccnd1 exon 4/5 locus results in exclusive
production of cyclin D1b
To develop robust genetic systems of cyclin D1b production under
the endogenous promoter, a gene-targeting construct was generated
wherein all C-terminal-encoding components of the murine Ccnd1
gene were replaced with the C-terminal sequences responsible for
human cyclin D1b production. As shown in Fig 1A, this was accomplished by replacing murine exon 4, intron 4, exon 5, and 30 UTR
with human exon 4 and intron 4 encoding sequences. The use of
human exon 4/intron 4 and removal of murine exon 5/30 UTR were
necessary to both eliminate the possibility of full-length transcript a
production (encoding cyclin D1a), and to foster production of transcript b, encoding the unique C-terminus harbored by cyclin D1b.
Furthermore, this strategy preserves upstream splicing events of the
Ccnd1 transcript, which more accurately reflects the biochemical
conditions responsible for cyclin D1b production.
Generation of cyclin D1b knock-in mice was accomplished
through electroporation of the targeting knock-in construct (Fig 1A)
into murine embryonic stem cells. Heterozygous clones were identified by Southern blot analysis and injected into developing mouse
blastocysts, generating chimeric mice. Chimeric mouse pairs were
subsequently bred to produce heterozygous wild-type/cyclin D1b
mice (here-to-after referred to as ‘+’ and ‘KI’ alleles respectively),
which were then crossed to produce homozygous cyclin D1b
knock-in mice (Ccnd1KI/KI). Primers specific for murine exon 5 (‘+’
allele) or human intron 4 (‘KI’ allele) were used to distinguish
between the respective genotypes (Fig 1B, top), and confirm
somatic incorporation of the KI allele (Fig 1B, bottom). To verify
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Figure 1. Humanization of the Ccnd1 exon 4/5 locus results in exclusive production of cyclin D1b.
A Representative schematic of the targeting construct generated to humanize the Ccnd1 exon 4/5 genomic locus to produce cyclin D1b.
B Top: Schematic of primer pairs designed to discriminate between wild-type and knock-in alleles. Bottom: Representative genotyping of Ccnd1+/+, Ccnd1+/KI, and
Ccnd1KI/KI mice validating specificity of the primer pairs and somatic insertion of the targeting construct.
C PCR analysis of transcript b expression in organs harvested from Ccnd1+/+ and Ccnd1KI/KI mice, demonstrating production of transcript b specifically in KI mice. Gapdh
serves as a control (NTC, Non-template control).
D Immunoblot from parallel samples in (C) utilizing antisera specific to the 33 amino acids generated by human CCND1 intron 4. Lamin B serves as a control. Arrow
indicates the cyclin D1b band.

that humanization of the Ccnd1 locus resulted in the production of
transcript b, individual tissues previously reported to express
cyclin D1 were harvested from Ccnd1+/+ and Ccnd1KI/KI mice and
analyzed for cyclin D1 expression. Primer pairs specific to the
N-terminus of cyclin D1 (common to both transcript a and b) were
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used to confirm expression in each tissue by PCR (Fig 1C). Further
investigation using unique primer sets validated exclusive production of transcript b in Ccnd1KI/KI animals, and expression was
mirrored at the protein level in all tissue types tested (Fig 1D),
affirming that humanization of the Ccnd1 locus results in the
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exclusive production of cyclin D1b. Thus, this system provides a
unique tool to study cyclin D1b function under the control of its
endogenous promoter and in the genetic absence of cyclin D1a.
Unique functions of cyclin D1b in development
Ccnd1KI/KI mice exhibit post-natal growth retardation
While several murine models have been characterized which mutate
and/or toggle cyclin D1 expression, to date no genetic systems had
been generated which assess cyclin D1b function under the endogenous promoter in vivo. Crosses between Ccnd1+/KI mice (> 20
mating pairs across multiple generations) revealed that Ccnd1KI/KI
mice are born in typical Mendelian ratios (Supplementary Fig S1A),
suggesting that cyclin D1b expression does not result in embryonic
lethality. At birth, Ccnd1KI/KI pups were indistinguishable from wildtype littermates, as noted by virtually identical size (Fig 2A) and
mass (Fig 2B). However, by 3 weeks of age, a significant reduction
in size and weight was noted in the Ccnd1KI/KI mice, which persisted
over a period of 8 weeks and was independent of gender (Fig 2C).
Further analysis of individual organ weight (adjusted for total body
mass) revealed no significant difference between Ccnd1+/+,
Ccnd1+/KI, or Ccnd1KI/KI animals, suggesting that diminished organ
size was not causative for the observed reduction in mass. Notably,
the growth rate of all animals was similar between 3 and 8 weeks of
age, indicating that the reduction in size and mass occurs early in
post-natal development. Interestingly, previous work modeling
cyclin D1 loss (Ccnd1/) in an identical genetic background found
a similar growth phenotype during early development, which
persisted throughout the lifetime of Ccnd1/ animals (Sicinski
et al, 1995). Given the similarity between these two models, these
data support the concept that cyclin D1b induction is not sufficient
to restore the growth retardation phenotype observed in Ccnd1/
mice and highlights the functional differences between the two
cyclin D1 isoforms.
CcndKI/KI mice phenocopy neuromuscular and death phenotypes of the
Ccnd1/ mouse
The latent growth phenotypes common between the Ccnd1KI/KI and
the Ccnd1/ mice (on identical genetic backgrounds) suggest the
presence of overlapping but non-redundant functions of cyclin D1b
and cyclin D1a. To further explore this concept, Ccnd1KI/KI mice
were initially evaluated for the presence of a neuromuscular hindlimb abnormality (leg clasping), which occurs with high frequency
in mice that harbor cyclin D1 loss but is not present in Ccnd1+/+ or
Ccnd1+/ animals. Consistent with the growth phenotypes
described above, this phenotype was observed in all Ccnd1KI/KI mice
examined (Fig 2D, right) and was 100% penetrant across generations. While the severity with which Ccnd1KI/KI animals clasp limbs
varied (with the smallest animals tending to present with the most
severe clasping), it was evident in all Ccnd1KI/KI mice beginning at
3 weeks of age and persisted.
While both Ccnd1KI/KI and Ccnd1/ mice display leg clasping
and latent growth phenotypes in early development, notable differences become apparent through aging. Ccnd1/ animals show
minor frequency of spontaneous morbidity beginning at 3 weeks
(Sicinski et al, 1995), observable up to 2 months of age. This phenotype was also apparent in Ccnd1KI/KI animals beginning at 1 month,
the sudden death phenotype persisted up to 3 months, with no
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preceding signs of lethargy, malnutrition, or dehydration (Supplementary Fig S1A). Animals that survived beyond 3 months did not
succumb to sudden death. Initial tests were undertaken to determine
whether critical organ functions were compromised in Ccnd1KI/KI
mice. Analyses of complete blood counts and serum biochemistry
analyses showed no evidence of hematopoietic, liver, pancreatic, or
kidney dysfunction in either Ccnd1+/+ or Ccnd1KI/KI mice. Accordingly, no clinically significant abnormalities were histologically
apparent in mice aged to 9 months in the heart, liver, lung, brain,
spleen, small intestine, colon, kidney, adrenals, skin, bone/bone
marrow, urinary bladder, stomach, testes, uterus, thyroid, or
thymus of either the Ccnd1KI/KI or Ccnd1+/+ animals. Analysis of
cardiac function utilizing echocardiogram revealed no major defect
in overall cardiac output (Supplementary Fig S2A) between genotypes, but echo-derived mass and thickness of the left ventricle were
consistently diminished in Ccnd1KI/KI animals (Supplementary Fig S2B)
suggesting a potential role for cyclin D1/1b in this tissue type.
Collectively, these data suggest the low frequency of sudden death
observed in Ccnd1KI/KI mice is complex, and further highlight the
divergent action of cyclin D1b on developmental phenotypes.
Ccnd1KI/KI mice exhibit normal mammary and retinal development
Female mice lacking cyclin D1 expression are unable to effectively
lactate in response to pregnancy (Sicinski et al, 1995), resulting in
neonatal death. Consonantally, litters born of Ccnd1KI/KI mothers
exhibit a similar death response within 1 week of birth (notably,
not seen with Ccnd1+/KI mothers). This was not attributable to birth
defects, as this phenotype is readily reversed by replacing Ccnd1KI/KI
females with Ccnd1KI/+ or Ccnd1+/+ foster mothers after birth
(Supplementary Fig S1B). Interestingly, this was not due to lack of
mammary gland development in Ccnd1KI/KI; analysis of mammary
gland branching and histoarchitecture post-pregnancy uncovered no
appreciable differences between Ccnd1KI/KI or Ccnd1+/+ females
(Supplementary Fig S1C). This suggests that the observed neonatal
death from Ccnd1KI/KI mothers is not due to deficient mammary
growth and that other (potentially neurological) behaviors likely
underlie such phenotypes.
Of all the phenotypes associated with Ccnd1/ mice, the most
penetrant and dramatic is improper development of the retina. In
Ccnd1/ mice, layers of the retina fail to develop fully, resulting in
retinal hypoplasia and limited visual capacity (Sicinski et al, 1995).
Thus, to define the consequence of the genetic switch to cyclin D1b
on retinal phenotypes, expression of individual cyclin D1 isoforms
was initially characterized in whole-eye lysates. As shown in Fig 2E,
top, both cyclin D1a (lanes 1, 2) and cyclin D1b (lanes 2, 3) were
readily detected. Furthermore, hematoxylin and eosin (H&E) staining of retinal tissue from aged-matched Ccnd1KI/KI mice showed that
the size of the individual retinal layers in Ccnd1KI/KI mice is indistinguishable from that in Ccnd1+/+ (Fig 2E bottom, quantified to the
left). This is in contrast to Ccnd1/ mice, where dramatic hypoplasia of retinal layers was confirmed (Supplementary Fig S1D).
Thus, whereas cyclin D1b insufficiently rescues the leg clasping and
early sudden death phenotypes associated with cyclin D1a loss, the
retinal phenotype is completely rescued by conversion to cyclin
D1b. These collective data suggest that cyclin D1b harbors overlapping but non-redundant functions with cyclin D1a (Fig 2F), and
reinforces the concept that cyclin D1b holds unique functions that
impinge upon development.
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Figure 2. Cyclin D1b selectively rescues Ccnd1/ phenotypes.
A Neonates from 2 independent litters of Ccnd1+/KI × Ccnd1+/KI crosses were sacrificed at birth and genotyped. Mice were organized by genotype and total size
measured.
B Mass of neonates was calculated at birth and average mass quantified (n = at least 4 mice per group).
C Mice were weighed weekly, and growth is plotted as the average mass of each genotype/week (left: male, right: female, n > 5 per gender and genotype).
D Mice were held by the tails and analyzed for the leg clasping phenotype. Representative images of Ccnd1+/+ and Ccnd1KI/KI age-matched mice are shown (n > 10 for
each group).
E Top: Individual whole-cell lysates were generated from the eyes of mice of each genotype and analyzed for expression of +/+ cyclin D1 (cyclin D1a) and KI/KI cyclin
D1b via immunoblot using antisera specific to each isoform. Bottom: Representative H&E staining of retinal tissue from Ccnd1+/+ and Ccnd1KI/KI mice showing
individual layers of the retina. The ganglion cell layer and inner plexiform layer (G + IPL), inner nuclear layer (INL), and outer nuclear layer (ONL) were quantified
(right). Images were taken at 400× magnification.
F Comparison of the phenotypes described in the Ccnd1/ mouse with those observed in the Ccnd1KI/KI mouse, previously described (Sicinski et al, 1995).
Data information: n = at least 4 for each genotype. Error bars represent the standard error of the mean (SEM), and significance was determined using a two-tailed
Student’s t-test.
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Genetic evidence for cyclin D1b as a bona fide oncogene
The model of endogenous cyclin D1b characterized above revealed
unique contributions of cyclin D1b to developmental processes
and illuminated the first evidence of biological distinctions
between the two isoforms. In human cancer, high cyclin D1b is
associated with the poor outcome (Li et al, 2008; Millar et al,
2009), and cyclin D1b overexpression transforms cells of mesenchymal origin (Lu et al, 2003). However, the oncogenic capacity
of cyclin D1b in the absence of endogenous cyclin D1a or via the
endogenous CCND1 promoter had not been demonstrated. Murine
models of forced cyclin D1a overexpression show limited oncogenic capacity (Wang et al, 1994); moreover, tumor development
is not fully penetrant and is quite latent. Similar results were
observed herein utilizing models of cyclin D1b expression driven
from the endogenous promoter. Ccnd1KI/KI mice up to 9 months of
age showed no significant difference in the number hyperplastic or
neoplastic lesions compared to age-matched wild-type controls,
though animals are currently being aged further to quantify tumor
formation rates. To expedite generation time and define the potential of an endogenous shift to cyclin D1b on tumor formation,
murine adult fibroblasts (MAFs) were generated from the peritoneum of Ccnd1+/+ and Ccnd1KI/KI mice (Fig 3A). Similar models
that modulated the expression of various oncogenes and tumor
suppressors have demonstrated that MAF lines are an effective
tool with which to study both biochemical and transformation
phenotypes (de Napoles et al, 2004; Powers et al, 2004; Dean
et al, 2010; Bourgo et al, 2011) and as such, each line was
assayed for evidence of cellular transformation. Exclusive expression of respective cyclin D1 isoforms was initially confirmed by
immunoblot using an antibody common to both cyclin D1a and
cyclin D1b (Fig 3B). Individual Ccnd1+/+ and Ccnd1KI/KI lines were
mixed with Matrigel and injected subcutaneously into the flanks of
nude mice. As is shown in Fig 3C, Ccnd1+/+ control cells were
non-tumorigenic. By contrast, Ccnd1KI/KI cells formed tumors by
~15 weeks with high penetrance (80%). H&E staining confirmed
the tumors were of mesenchymal origin, and displayed hallmarks
of neoplasia including (1) invasion into the subcutaneous fat, (2)
nuclear and cytoplasmic atypia, and (3) prevalence of high mitotic
figures (Fig 3D, left). These data are the first to demonstrate that
physiological levels of cyclin D1b are sufficient to promote tumorigenesis in immortalized cells, and provide evidence to support its
role as an oncogene.
Notably, characterization of cyclin D1 levels in both the Ccnd1+/+
and Ccnd1KI/KI lines uncovered reduced expression of cyclin D1b
compared to cyclin D1a at both the protein and transcript level
(Fig 3B). Since elevated D-type cyclins have been associated with
tumor formation and genome instability in vivo (Wang et al, 1994;
Casimiro et al, 2012), the effect of elevated levels of cyclin D1a
and cyclin D1b was next interrogated for tumor kinetics in vivo.
Isogenic cell lines were engineered to overexpress either cyclin
D1a (in Ccnd1+/+ MAFs +/+-D1a) or cyclin D1b (in Ccnd1KI/KI
MAFs- KI/KI-D1b) (Fig 3E), subcutaneously implanted into the
flanks of nude mice, and monitored for tumor growth over a
period of 1 year. Consistent with previous data, the induction of
cyclin D1a in Ccnd1+/+ lines was weakly tumorigenic, increasing
tumor formation of that cell type by ~20% (Fig 3F). Importantly,
there was no observable increase in the tumor kinetics or

ª 2015 The Authors

EMBO Molecular Medicine

frequency between vector control and cyclin D1b-overexpressing
Ccnd1KI/KI lines. Analysis of pathological hallmarks of transformation in KI/KI-D1b lines found similar characteristics to that of the
vector control (Fig 3D, right), and no difference in proliferative
capacity (as measured by Ki67) (Fig 3G). Taken together, these
data demonstrate that the presence of cyclin D1b can promote
transformation and tumor formation and that elevated levels of this
isoform are not required for its oncogenic activity.
Previous studies have suggested that mammary transformation
and tumor development are critically dependent upon the kinase
activity of cyclin D1 (Landis et al, 2006), whereby knock-in of a
kinase dead allele of cyclin D1 (K112E) dramatically inhibited tumor
formation within this tissue type (Landis et al, 2006). To define the
ability of cyclin D1b to cooperate with oncogenes reliant on the
cyclin D1/CDK4 pathway, lentivirus containing vector- or h-RASexpressing constructs was introduced to both Ccnd1+/+ (+/+ h-Ras)
and Ccnd1KI/KI (KI/KI h-Ras) lines. While no anti-proliferative effects
were noted in KI/KI h-Ras lines, +/+ h-Ras lines underwent
sustained cell cycle arrest. Consistent with this observation, analysis
of senescence markers (b-galactosidase activity) uncovered intense
positive blue staining only in the +/+ h-Ras line (+/+ vec lines were
negative) (Fig 4A), demonstrating that in this cell type, h-Ras induction promotes oncogene-induced senescence, consistent with previous findings (Weyemi et al, 2012; Peeper et al, 2002). Given
that KI/KI h-Ras lines were refractory to this effect (Fig 4B), +/+ Vec,
KI/KI vec, and KI/KI h-Ras lines were assayed their ability to form
colonies in soft agar, a known marker of transformation. Consistent
with tumor formation in vivo (Fig 3A), +/+ vec lines were unable to
grow in soft agar, while KI/KI vec cells were capable of forming
colonies after 4 weeks (Fig 4C). Strikingly, the addition of h-Ras
enhanced the ability of these cells to grow in soft agar, increasing
colony number by ~fivefold. This effect was further demonstrated
in vivo, where KI/KI h-Ras lines were capable of enhancing tumor
formation kinetics by ~5.5-fold over KI/KI vec cells (Fig 4D).
Furthermore, analysis of proliferative markers within these tumors
found an increase in the number of Ki67-positive cells in the KI/KI
h-Ras tumors, demonstrating the enhanced proliferative capacity of
these cells (Fig 4E). Collectively, these data provide evidence to
support the role of cyclin D1b as critical oncogenic ‘hit’, functioning
to promote cellular transformation and bypass of senescence
programs initiated by the further oncogenic insult.
Genetic switch to cyclin D1b induces serum independence
The concept that endogenously derived cyclin D1b induces transformation is significant and highlights distinctions from cyclin
D1a, which requires overexpression to serve as an oncogene.
Given the unexpected nature of these findings, Ccnd1KI/KI cells
were used to characterize the molecular consequence of cyclin
D1b expression. To examine cyclin D1b distribution/stability in
the absence of a constitutively active promoter, Ccnd1+/+ and
Ccnd1KI/KI cells were arrested in each phase of the cell cycle and
expression of individual cyclin D1 isoforms determined. As shown
in Fig 5A, cyclin D1a levels peaked in G1, and diminished as a
function of cell cycle progression (cyclin A2 and cyclin B1 serve as
late S and G2/M phase-specific controls). Cyclin D1b expression
mimicked that of cyclin D1a, suggesting that both isoforms are
regulated in a similar fashion throughout the cell cycle. These data
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Figure 3. Genetic evidence for cyclin D1b as a credentialed oncogene.
A Murine adult fibroblasts (MAFs) were harvested from the peritoneum of Ccnd1+/+ and Ccnd1KI/KI mice, and stable cell lines were generated utilizing a 3T3 protocol.
B Indicated passage-matched MAF lines were grown to 70% confluency and then harvested for RNA and protein extraction. Top: qPCR analysis of cyclin D1 transcript
using primer pairs common to both transcript a and transcript b. Bottom: Immunoblot of cyclin D1 levels in Ccnd1+/+ and Ccnd1KI/KMAF lines using an antibody
common to both isoforms.
C Percentage of tumor-free mice post-injection of 1 million cells mixed with Matrigel (1:1 ratio) into the flanks of nude mice over a period of 10 months (n = 10 per
genotype).
D Indicated tumors were harvested 3 weeks after detectable tumor formation, fixed in formalin, and stained with H&E. Tumors were analyzed for features of
malignancy by a board-certified veterinary pathologist. Arrows indicate the specific tumor-associated features noted. Top panels were taken at 40× magnification,
and lower panels were taken at 400× magnification.
E Ccnd1+/+ or Ccnd1KI/KI MAF lines were stably transfected with either cyclin D1a (+/+), cyclin D1b (KI/KI) or vector control constructs. After selection with puromycin,
individual lines were assessed for the induction of cyclin D1a in the +/+ line and cyclin D1b in KI/KI lines via immunoblot.
F One million cells from the indicated stable cell lines were injected subcutaneously into the flanks of nude mice and monitored for tumor formation over a period of
365 days. Indicated time points represent time of palpable tumor detection and are plotted as % of tumor-free mice over time.
G Sections from KI/KI vec and KI/KI-D1b tumors were stained for the proliferative marker Ki67. Three random fields from each tumor were quantified for Ki67 positivity,
and are plotted as the mean ratio of Ki67-positive cells/total cell number for each individual tumor.
Data information: Error bars represent  SEM.
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Figure 4. Cyclin D1b cooperates with h-Ras to drive tumorigenesis.
A Passage-matched Ccnd1+/+ or Ccnd1KI/KI MAF lines were infected with lentivirus containing vector control or h-Ras constructs. Cells were selected with puromycin for
14 days and assayed for b-galactosidase activity. DAPI serves as a control for cell number. Images were taken at 200× magnification with insets taken at 400×
magnification.
B The indicated cell lines were grown in complete media and assayed for h-Ras expression via immunoblot. Lamin B serves as a loading control.
C Cells were plated in soft agar and allowed to grow for a period of 3 weeks. Plates were then washed, fixed, and stained with 0.01% crystal violet. Colonies greater
than 50 lm were counted and are plotted (top). Representative images of colony growth are shown for each cell line. Images were taken at 40× with insets taken at
200× magnification.
D Indicated MAF lines were injected subcutaneously into the flanks of nude mice as in (A), and tumor incidence is plotted as % of tumor-free mice over time (n = 10).
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are plotted as a % of total cell number, n = 5 (right: representative images). Images were taken at 400× magnification.
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thus demonstrate that the oncogenic activity governed by cyclin
D1b is independent of aberrant expression in later phases of the
cell cycle.
To further explore the consequence of cyclin D1b, the impact on
cell cycle kinetics was determined. As shown in Fig 5B, individual
MAF lines exclusively expressing cyclin D1a (Ccnd1+/+) or cyclin
D1b (Ccnd1KI/KI) demonstrated comparable expression of G1 and S
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phase CDK and cyclin components. RB phosphorylation at Ser-780
(an established site of CDK4/6 kinase activity) was maintained in
Ccnd1KI/KI cells, indicating that CDK4/6 kinase activity is preserved
in cyclin D1b-expressing cells. This was further validated in tissues
derived from age-matched Ccnd1+/+ and Ccnd1KI/KI animals
(Supplementary Fig S3A), which revealed that phosphorylation
of RB at S780 is comparable between +/+ and KI/KI tissues,
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Figure 5. Genetic switch to cyclin D1b promotes serum independence.
A Ccnd1+/+ and Ccnd1KI/KIMAF lines were arrested in G1, S, and G2/M phases of the cell cycle and expression of cyclin D1 isoforms determined by immunoblot. cyclin A2
and cyclin B1 serve as phase-specific cell cycle controls.
B Cells were plated in serum-proficient media and protein lysates generated from each genetic line. Individual D1 cyclins were immunoblotted to verify genetic identity
along with other essential cell cycle components. Lamin B serves as a control.
C Indicated cells lines were immunoprecipitated for CDK4 and analyzed for their ability to incorporate 32P-ATP into full-length RB substrate. Radioactive counts were
normalized to CDK4 activity of +/+ cell lines and adjusted for efficiency of CDK4 pull down as determined by densitometry. Data is representative of three
independent biological replicates.
D Indicated cell lines were plated in serum-proficient (10%) or serum-deficient (1%) media and total cell number counted at 24, 48, and 72 h in biological triplicate.
E Ccnd1+/+ and Ccnd1KI/KI MAF lines were transfected with a validated pool of siRNA directed against the N-terminus of the murine cyclin D1 transcript or control siRNA
in full serum. 48 h post-transfection cells were harvested and analyzed for biochemical markers of cell cycle kinetics via immunoblot. GAPDH and Lamin B serve as
controls.
F Cells were treated as (E), and incubated in the indicated serum concentration for 48 h. Cells were treated with BrdU for 1 h prior to harvesting and then stained for
BrdU incorporation. Three random fields from each of three biological triplicates were counted for BrdU incorporation via immunofluorescence and data is
represented as percent positive/total cell number.
Data information: Error bars represent  SEM, and statistical significance was determined using a two-tailed Student’s t-test. **P < 0.01, ***P < 0.001.

further suggesting that cells expressing cyclin D1b maintain active
CDK4/6 complexes. To more directly address this concept, the
ability of cyclin D1 isoforms to interact with and activate CDK4 was
determined in both +/+ and KI/KI models. Consistent with previous
reports, both cyclin D1a and cyclin D1b effectively interact with
CDK4 (Lu et al, 2003) (Supplementary Fig S3B). CDK4 kinase assays
uncovered a similar ability of CDK4 to phosphorylate RB in the presence of cyclin D1a (+/+ cells), or cyclin D1b (KI/KI cells, Fig 5C).
These findings are consistent with growth studies that demonstrated
nearly identical growth rates in serum-proficient conditions (Fig 5D,
left). However, when challenged with 1% serum, there was a
dramatic difference between the growth potential of Ccnd1+/+ and
Ccnd1KI/KI cells (Fig 5D, right). Parallel studies analyzing active
S phase via bivariate flow cytometry validated the growth patterns
in both serum-proficient (10%) and serum-deficient (1%) conditions (Supplementary Fig S3C), demonstrating that cyclin D1b
expression supports growth in serum-depleted conditions independent of aberrant expression throughout the cell cycle.
To define the dependence of such phenotypes on cyclin D1b
expression, a validated pool of siRNA targeting the N-Terminus of
murine cyclin D1 (common to both isoforms) was transfected into+/+
and KI/KI MAF lines and assessed for markers of proliferation. As
shown in Fig 5E, the introduction of siRNA resulted in a dramatic
reduction of both cyclin D1a and cyclin D1b. In Ccnd1+/+ cells, loss
of cyclin D1a resulted in a dramatic reduction in the proliferative
markers p-RB(S780) and cyclin A and correlated with 80% reduction
in bromodeoxyuridine (BrdU) incorporation under these conditions
(Fig 5F). Interestingly, loss of cyclin D1b in Ccnd1KI/KI cells resulted
in only modest reduction of p-RB(S780) and cyclin A, correlating with
only ~20% reduction in BrdU incorporation (Fig 5E and F, left). Of
importance, cyclin D1b expression was required for growth in serum
independent conditions, wherein loss of cyclin D1b resulted in a
substantial reduction in BrdU incorporation as compared to control
(Fig 5F). These findings strikingly reveal an independent capacity of
endogenous cyclin D1b to confer serum independence, consistent
with capacity of cyclin D1b to drive tumor formation in vivo.
Cyclin D1b expression promotes double-strand breaks and
PARP1 activity
Given the collective observations above that cyclin D1b elicits divergent effects on cellular transformation, and clinical observations

ª 2015 The Authors

that cyclin D1b expression is associated with therapeutic resistance,
it was imperative to challenge the impact of therapeutic intervention
and or genotoxic stress on cyclin D1b-driven tumor cells. Initially,
the presence of DNA damage was assessed in Ccnd1+/+ and
Ccnd1KI/KI by quantifying intrinsic p-H2AX and 53BP1 foci, established markers of DNA breaks and known metrics for genome integrity. As expected, a majority of the Ccnd1+/+ cells showed a low
frequency of both p-H2AX and 53BP1 foci/cell (Fig 6A). In contrast,
cells expressing endogenous cyclin D1b harbored increased doublestrand breaks, demonstrated by the enhanced prevalence of p-H2AX
and 53BP1 foci (Fig 6A, quantified right). These data were confirmed
in an independently derived Ccnd1KI/KI cell line (Supplementary
Fig S4A), suggesting that Ccnd1KI/KI cells maintain heightened intrinsic DNA damage. Furthermore, cyclin D1b was required to maintain
markers of DNA damage, as loss of cyclin D1b expression reduced
the levels of both p-H2AX and 53BP1 foci to those found in
Ccnd1+/+ control cells (Fig 6A, quantified right), suggesting that
cyclin D1b expression is associated with markers of DNA damage.
To further explore this concept, levels of auto-modified PARP-1
(known to increase in response to DNA damage) were assayed in
Ccnd1+/+ and Ccnd1KI/KI lines. As shown in Fig 6B, auto-modified
PARP-1 was low in Ccnd1+/+ control cells (lane 1), consistent with
the low frequency of p-H2AX foci. Conversely, Ccnd1KI/KI cells show
dramatically heightened levels of PARP-1 activity (lane 2 and
Supplementary Fig S4B), further demonstrating that cyclin D1b
expression promotes intrinsic DNA damage. To compare intrinsic
DNA damage signals to those induced in response to exogenous
genomic insult, control and Ccnd1KI/KI cells were treated with etoposide, known to induce double-strand breaks, and assayed for markers of DNA damage response. Cyclin D1a-expressing cells (Ccnd1+/+)
showed low levels of PARP-1 activity, which were enhanced in the
presence of genotoxic stress (Fig 6C lanes 1, 2). Increased PARP-1
activity was not due to a total increase in PARP-1, but correlated
with enhanced poly-ADP-ribose (PAR) and p-H2AX expression,
consistent with initiation of a DNA damage response. In contrast,
Ccnd1KI/KI cells showed high PARP-1 activity in the untreated
setting—strikingly, no further increase in PARP-1 activity or PAR
levels was observed after etoposide treatment (Fig 6C lanes 3 and
4). Consistent with the loss of DNA damage markers after cyclin
D1b depletion, loss of cyclin D1b resulted in a decrease in total
PAR levels (Fig 6D), which was not observed with cyclin D1a loss
in Ccnd1+/+ cells. These data indicate that PARP-1 is activated in
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Figure 6. Cyclin D1b expression promotes double-strand breaks and PARP-1 activity.
A Ccnd1+/+ and Ccnd1KI/KI cells were transfected with a pool of siRNA directed against the N-terminus of the murine cyclin D1 transcript or scramble control for 48 h
(as in Figure 5). Cells were then fixed and stained for markers of double-strand breaks (p-H2AX and 53BP1, 400× objective). Total number of foci for each cell was
quantified and represented as the % of cells with > 10 foci/cell (p-H2AX) or % of cells with > 2 foci/cell (53BP1). Error bars represent  SEM.
B Ccnd1+/+ and Ccnd1KI/KIMAF lines were grown in serum-proficient media for 24 h and probed for expression of auto-modified PARP1 via immunoblot. Gapdh and
cyclin D1b serve as controls.
C Cells were plated as in (B) and treated with 0.5 lM etoposide for 3 h. Cells were harvested and then probed for markers of DNA damage via immunoblot. Lamin B
serves as a control.
D Indicated MAF lines were treated as in (A) and harvested 48 h post-transfection. Cells were analyzed for total PAR levels via immunoblot. cyclin D1 levels serve as
siRNA validation controls.
E cyclin D1b expression was induced in the prostate cancer cell line LNCaP (previously described (Augello et al, 2014)) and stained for p-H2AX and 53BP1 foci as in (A)
via immunofluorescence (400× objective). Total number of foci/cell is reported for LNCaP vector control and cyclin D1b-expressing isogenic pairs in biological
triplicate.
F Isogenic pairs from (E) were grown in serum-proficient media for 24 h, harvested, and probed for total PAR levels via immunoblot.
Data information: Statistical significance was determined using a two-tailed Student’s t-test.*P < 0.05 **P < 0.01, ***P < 0.001.

cells that shift from cyclin D1a to cyclin D1b, thus further suggesting that cyclin D1b destabilizes genome integrity.
To ensure that the observed intrinsic DNA damage signals seen
in Ccnd1KI/KI cells were not due to a defect in p53 signaling, the p53
target gene Cdkn1a (p21) was analyzed before and after etoposide
treatment. As shown in Supplementary Fig S5A, an increase in
Cdkn1a transcript is readily seen as early as three hours posttreatment in both Ccnd1+/+ and Ccnd1KI/KI lines, which correlated
with an increase of p21 protein (Supplementary Fig S5B), suggesting
that Ccnd1KI/KI cells maintain a functional p53 pathway. As a further
control for specificity and relevance to human disease, the ability of
cyclin D1b to promote intrinsic DNA damage signals was determined in human prostate cancer models (a tumor type known to
shift from cyclin D1a to cyclin D1b (Comstock et al, 2009)).
Utilizing previously described isogenic models with or without
cyclin D1b expression (Augello et al, 2014), it was observed that
cells expressing cyclin D1b harbored a greater number of p-H2AX
and 53BP1 foci/cell than control (Fig 6D, right). The induction of
cyclin D1a alone had no significant effect on the prevalence of either
p-H2AX or 53BP1 foci (Supplementary Fig S6). Furthermore, PARP-1
activity was heightened in cyclin D1b-expressing cells, mirroring the
intrinsic DNA damage signals seen in Ccnd1KI/KI cell lines. Collectively, these data highlight novel actions of cyclin D1b in fostering
intrinsic DNA damage signals in multiple model systems, and offer
novel insight into the oncogenic action of this cyclin D1 isoform as
it relates to human disease.
Cyclin D1b expression sensitizes to senescence induced by
combined therapeutic challenge
The switch from cyclin D1a to cyclin D1b is observed in numerous
human malignancies and is associated with poor prognosis. Despite
this knowledge, delineation of mechanisms to target cyclin D1bpositive/cyclin D1b-driven tumor cells remains elusive. Building on
the observations herein, it was hypothesized that therapeutically
targeting DNA damage and PARP pathways individually or in combination would sensitize cells to cell cycle arrest and/or cell death.
Thus, control (Ccnd1+/+) and Ccnd1KI/KI cells were treated either with
the PARP inhibitor ABT-888, 5 Gy of radiation, or a combination and
analyzed for cell cycle progression. As shown in Fig 7A, both
Ccnd1+/+ and Ccnd1KI/KI cells showed similar proliferative kinetics
when unchallenged in normal growth conditions, and neither cell
type was affected by ABT-888 alone. In Ccnd1+/+ cells, treatment
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with 5 Gy IR diminished BrdU incorporation by ~10%, which was
unchanged with pre-treatment of ABT-888. Conversely, while
Ccnd1KI/KI cells responded similarly to 5 Gy IR alone, combination of
IR and ABT-888 dramatically inhibited BrdU incorporation (Fig 7A,
quantified right). The reduction in proliferative capacity was associated with altered morphology, indicative of senescence. As such,
cells were treated as above and then assayed for senescenceassociated b-galactosidase (b-Gal) activity. As shown, only a small
fraction of cells stained positive in the control and ABT-888-treated
conditions (Fig 7B, quantified bottom), and IR alone increased the
presence of b-Gal activity equally in both cell models. However,
there was a pronounced induction of b-Gal staining after combination treatment in the Ccnd1KI/KI line, nearly double that of the
Ccnd1+/+ control. Re-plating both the Ccnd1+/+ and Ccnd1KI/KI cells
(which were co-treated) determined that while control cells were
able to reengage the cell cycle and repopulate the dish after 96 h,
Ccnd1KI/KI cells were markedly unable to do so. These data thus
demonstrate that the intrinsic DNA damage and heightened PARP-1
activity seen in cyclin D1b-expressing cells may be exploited to
thwart growth of this cell type via combined therapeutic challenge.

Discussion
Here, a novel genetically engineered mouse model was used to
convert cyclin D1a to cyclin D1b, allowing for first-in-field analysis
of cyclin D1b in vivo and under control of the endogenous promoter
(Fig 1). Notably, cyclin D1b expression phenocopied only a selected
subset of Ccnd1/ mouse aberrations (Fig 2), supporting the concept
that cyclin D1b harbors distinct functions from that of cyclin D1a.
Parallel studies utilizing isoform-specific models revealed the oncogenic potential of cyclin D1b, which further cooperated with known
oncogenes to promote cellular transformation and tumor growth at
high frequency (Figs 3–5), was associated with persistent DNA
damage signals (Fig 6). Furthermore, Ccnd1KI/KI cells were sensitized
to cell cycle arrest and senescence though combined therapeutic
intervention (Fig 7), providing the first preclinical evidence of
mechanisms to target cyclin D1b-expressing tumors. Collectively,
this new model system unveiled novel functions of cyclin D1b in
both development and tumorigenesis (Fig 8) and identified means
to target tumor cells that depend upon cyclin D1b expression.
Genetic switching from cyclin D1a to cyclin D1b unmasked
unique functions of this isoform in development and homeostasis.
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Figure 7. Cyclin D1b expression sensitizes cells to senescence induced by therapeutic challenge.
A Ccnd1+/+ and Ccnd1KI/KIMAF lines were grown in serum-proficient media for 24 h. Cells were then treated with control DMSO or 2.5 lM of the PARP inhibitor ABT-888.
One hour post-treatment, the indicated lines were treated with 5 Gy of radiation. Cells were then allowed to recover for 48 h, after which BrdU was added for 1 h,
and then harvested for bivariate flow cytometry. Representative traces for each condition are shown (left) and BrdU incorporation of biological triplicates was
quantified (right).
B Cells were plated and treated as in (A). Forty-eight hours post-treatment, cells were fixed and stained for markers of senescence (b-galactosidase activity). Cells
positive for the staining (blue) were quantified for each condition (400× magnification) and reported as a percentage of the total population (right). Plates treated in
parallel with both IR and ABT-888 were harvested at 48 h via 1× trypsin and re-plated in serum-proficient media. Cells were allowed to grow for 96 h and were then
stained with crystal violet (4× objective, with inset at 200× magnification, boxes highlight area of magnified images).
Data information: Error bars represent  SEM, and statistical significance was determined using ANOVA (A) or a two-tailed Student’s t-test (B). *P < 0.05,
***P < 0.001.

Data herein demonstrated that Ccnd1KI/KI mice displayed several
notable phenotypes consistent with genomic loss of cyclin D1 which
include (1) delayed post-natal growth kinetics, (2) neuro/muscular
limb dysfunction, and (3) low frequency of early onset death. Interestingly, Ccnd1KI/KI animals displayed no evidence of the hallmark
retinal hypoplasia and mammary deficient growth phenotypes seen
in multiple models of Ccnd1 loss (Sicinski & Weinberg, 1997; Landis
et al, 2006). Collectively, these data demonstrate that cyclin D1b
harbors overlapping but non-redundant functions with that of
cyclin D1a, and provide the first in vivo evidence of divergent
biochemical action of this variant. Insight into possible underlying
mechanisms of cyclin D1b function was gained from previous
models of cyclin D1 deregulation aiming to dissect the cell cycle
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from transcriptional functions of cyclin D1a. In an identical genetic
background, knock-in of the kinase activation dead mutation
(K112E) of cyclin D1 (Ccnd1KE/KE) rescued the retinal hypoplasia and
mammary phenotypes of the Ccnd1/ mouse, but not the growth
retardation, or leg clasping phenotypes (Landis et al, 2006). These
data are consistent with the known reliance on the transcriptional
functions of cyclin D1 for retinal and mammary development and
demonstrate that the cell cycle functions of cyclin D1 are required to
rescue other phenotypes seen upon Ccnd1 loss. The similarity
between the Ccnd1KE/KE and Ccnd1KI/KI models thus suggests that
endogenous production of cyclin D1b is not sufficient to fully engage
the cell cycle machinery (CDK4/6 complexes) in normal tissue,
and supports the concept that cyclin D1b functions as a potent

ª 2015 The Authors

Published online: March 18, 2015

Michael A Augello et al

EMBO Molecular Medicine

Consequence of the conversion to cyclin D1b

Ccnd1-/- Phenotypes
Not Observed

ºTranscriptionally Regulated
Retinal Hypoplasia
º Mammary Deficient Growth

Alternative
Splicing
Maintained

º Growth Retardation
º Leg Clasping

Novel

º Sudden Death
º Heart Development

Oncogenic Activity
Intrinsic DNA
Damage
Serum Independent
Growth

Senescence

ABT-888
PARP1 Activity

Genomic
Insult

Tumor
Growth

Figure 8. Model of cyclin D1b function in development and tumorigenesis.
Top: Comparison of the observed phenotypes noted in the Ccnd1KI/KI and Ccnd1/ mice (Sicinski et al, 1995). Bottom: Summation of the pro-oncogenic phenotypes associated
with cyclin D1b expression in cell-based models.

transcriptional regulator in vivo. Furthermore, the novel phenotypes
of Ccnd1KI/KI mice (in echocardiographic ventricular wall thickness/
mass and sudden death) indicate that the transcriptional functions of
cyclin D1b are divergent from that of full-length cyclin D1a. Given
the established transcriptional roles of cyclin D1b in disease
progression, future efforts will be aimed at defining the underlying
mechanisms behind cyclin D1b-mediated transcriptional regulation
and its role in both normal and malignant cellular processes.
In addition to the unique developmental functions of cyclin D1b,
novel observations were made regarding the impact of cyclin D1b on
neoplastic transformation. Data herein demonstrated that cyclin D1b
induced transformation of immortalized cells generate tumors with
high frequency (Fig 4). In contrast, wild-type cells were non-malignant, and forced overexpression of cyclin D1a (+/+ cells) or cyclin
D1b (KI/KI) cells had little impact on the tumorigenicity of either
line, demonstrating that the a major oncogenic function of cyclin D1
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is likely manifest through the induction of cyclin D1b rather than its
overexpression. Furthermore, only cells expressing cyclin D1b were
able to efficiently proliferate after the induction of h-Ras, this is, in
stark contrast to those expressing cyclin D1a which rapidly underwent
oncogene-induced senescence (as determined via b-galactosidase
activity). These data suggest that the induction of cyclin D1b can act
as a critical ‘hit’ during tumorigenesis which can facilitate the accumulation of further oncogenic events which cooperate to drive tumor
formation and progression. Collectively, these data thus provide the
first genetic evidence for cyclin D1b as an oncogene, and implicate
cyclin D1b as a potential biomarker of disease progression.
Although hyperplastic and neoplastic lesions were observed in
some Ccnd1KI/KI mice, the frequency of occurrence did not differ
from that of Ccnd1+/+ animals. While further studies are needed,
the observed frequency of neoplasms is consistent with previous
models of cyclin D1a deregulation in similar backgrounds (Wang
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et al, 1994). It is notable that even transgenic models of forced cyclin
D1a overexpression show quite limited capacity for tumor formation, which is latent, and requires co-expression of the Erbb2 oncogene for robust tumor induction in younger mice (Wang et al, 1994).
Furthermore, transgenic murine models harboring forced expression
of mutations in the cyclin D1a PEST domain (known to promote
cyclin D1a stability) require greater than 12 months for significant
tumor induction (Gladden et al, 2006). Collectively, these data
suggest that cellular transformation that results due to deregulation
of cyclin D1a is a latent event. Given the potent functions of cyclin
D1b on tumor formation described above, it will be essential to
define the frequency and distribution of cyclin D1b induction across
multiple tumor types, to more completely understand the contribution
of this isoform in malignant transformation and tumor progression.
The finding that endogenous expression of cyclin D1b independently promotes transformation of immortalized cells represents a
significant advance in our understanding of the differing oncogenic
capacity of cyclin D1 variants in tumor biology. Further, an unexpected link between cyclin D1b and DNA damage signals was
discovered, wherein cyclin D1b-expressing cells harbor elevated
levels of p-H2AX and 53BP1 foci as well as PARP-1 activity (Fig 6).
Previous in vitro models of cyclin D1 depletion described a critical
role of cyclin D1a in the DNA damage response pathway, wherein
cyclin D1a was necessary for BRCA1 recruitment to sites of damage,
and initiation of repair cascades (Jirawatnotai et al, 2011). Furthermore, mutations in the cyclin D1 PEST domain have been shown to
promote cyclin D1a stability, which resulted in inappropriate
expression throughout the cell cycle, culminating in aberrant assembly of replication machinery and DNA damage signals (Aggarwal
et al, 2007). While it is tempting to speculate that damage signals
observed in cyclin D1b-expressing cells originated from either of
these mechanisms, data herein suggest that the pathways are disparate. Indeed, analyses of cyclin D1b expression across the cell cycle
closely mimicked that of cyclin D1a, demonstrating that despite
lacking PEST encoding sequences, cyclin D1b is regulated in a similar temporal and kinetic manner to that of cyclin D1a (Fig 5). Additionally, no difference was found in the proliferative indices
between cyclin D1b-expressing and wild-type cells post-ionizing
radiation (Fig 7), suggesting that DNA damage repair pathways
(responsible for resolution of double-strand breaks) are not
compromised in cyclin D1b-expressing cells. These data thus
support the concept that the mechanisms underlying the intrinsic
damage signals in cyclin D1b-expressing lines are likely independent
of major defects in DNA damage or cell cycle pathways. Interestingly, recent evidence suggested that the functions of PARP-1 extend
beyond DNA damage repair (Luo & Kraus, 2012). Critical roles in
transcriptional regulation have recently been attributed to PARP-1
activation, which impact a diverse array of biological processes
(including inflammation, cell growth, survival, and apoptosis) (Luo
& Kraus, 2012; Schiewer et al, 2012a,b; Koh et al, 2005; Rajamohan
et al, 2009). It has been proposed that PARP-1 functions as a cellular ‘rheostat’, wherein the intensity of cellular stress dictates the
level of PARP-1 activation and subsequent biological response (Luo
& Kraus, 2012). Thus, given the tumor-associated transcriptional
functions of cyclin D1b, and the herein established link between
PARP-1 activity and cyclin D1b expression, it will be critical to
determine whether the two transcriptional networks cooperate to
promote transformation. Future efforts will focus on the defining
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the dependence of cyclin D1b-expressing cells on PARP-1 transcriptional functions, and delineate the networks responsible for both
heightened PARP-1 activity and p-H2AX foci.
Recent evidence has demonstrated that PARP-1 activity is
enhanced in selected tumors and likely contributes to tumor
progression (Brenner et al, 2011; Do & Chen, 2013; Luo & Kraus,
2012; Schiewer et al, 2012a,b; Kedar et al, 2012; Horton & Wilson,
2013; Horton et al, 2014; Schiewer & Knudsen, 2014). This concept
is supported by clinical evidence demonstrating PARP-1 suppression
can delay tumor progression (Fong et al, 2010). Consistent with
these findings, cyclin D1b-expressing cells were sensitized to cell
cycle arrest and senescence by combined PARP inhibition and ionizing
radiation. The robust response observed with combination treatment
in cyclin D1b-expressing lines indicates that PARP function is required
for initiation of an efficient repair response to genotoxic stress in these
cells. Given the heightened p-H2AX foci level and sustained PARP-1
activation state observed in cyclin D1b-expressing lines, these cells
appear reliant on PARP-1 signaling cascades for genomic maintenance. Consonantly, a similar dependence on PARP-1 activity has
been demonstrated clinically, where PARP-1 inhibition effectively
limited tumor growth in BRCA2/1-mutated tumors (Fong et al,
2010), and showed single-agent efficacy in patients with advanced
castration-resistant prostate cancer (a tumor type and stage known
to express high levels of cyclin D1b) (Fong et al, 2010; Sandhu et al,
2010). Taken together, cyclin D1b could potentially serve as a novel
biomarker of response to therapeutic intervention, and critical next
steps will aim to characterize key interactors and downstream
pathways in cyclin D1b tumors, which govern this response.
In summary, the present study describes the first-in-field model
of the switch from cyclin D1a to cyclin D1b and demonstrates overlapping but non-redundant functions of this isoform in vivo. Further,
these data provide the first genetic evidence for cyclin D1b as an
oncogene and uncovered novel links between cyclin D1b expression
and the DNA damage and PARP1 networks. These unexpected
results provided the first preclinical evidence of a method to specifically target cyclin D1b-expressing tumors and serve as the rationale
to develop cyclin D1b expression as a novel biomarker of therapeutic response.

Materials and Methods
Generation of Ccnd1KI/KI mice
Design of the knock-in targeting constructs that humanize the
murine Ccnd1 locus to produce cyclin D1b in the C57BL6/129 mixed
background is described in Fig 1A. Generation and cloning of targeting constructs, embryonic injection and selection, clone verification,
and generation of chimeric mice were conducted by InGenious
Laboratories LLC. Validation of the cyclin D1b knock-in allele was
performed using PCR from genomic DNA (100 ng) using the primers
(Murine Ccnd1 exon 3 – 50 AGT GCC ACT TAG GTG TCT CCA30 ,
Murine Ccnd1 exon 5 – 50 ACC AGC CTC TTC CTC CAC TT30 , and
human CCND1 intron 4 – 50 TCT GGA GAG GAA GCG TGT GAG G 30 )
(Fig 1). Mice were housed in animal facilities within the Kimmel
Cancer Center at Thomas Jefferson University, and all protocols
utilized for this study were approved by the Institutional Animal
Care and Use Committee (IACUC) at Thomas Jefferson University. If
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not otherwise stated all mice utilized for the study were male,
between the ages of 4 and 6 months.

(Schiewer et al, 2012)). A BD LSR II flow cytometer was used to sort
10,000 single cells per biological replicate, and FlowJo software was
utilized to gate for BrdU incorporation.

Immunoblotting
Lysates from either animal tissue (100 lg) or cell lines (20–30 lg)
were run on a 10% acrylamide SDSPAGE gel via gel electrophoresis,
transferred to a PDVF membrane at 85 V for 1 h in transfer buffer
(20% methanol, 0.1% SDS, 0.58% Tris base, 2.4% glycine), blocked
in 5% milk buffer (TBST) for 1 h at room temperature, and then
were probed with the given antibody overnight at 4C.
Antibodies
Antibodies used for immunoblotting, immunohistochemistry,
immunofluorescence, and flow cytometry include the following:
cyclin D1b (previously described (Comstock et al, 2009)), cyclin D1a
(Ab-4; NeoMarkers RB-212-P), cyclin A (C-19 sc-596; Santa Cruz),
CDK4 (IP C-22 sc-260, IP and immunoblot H-22 sc-601; Santa Cruz),
GAPDH (FL-335 sc-25778), pp-RB S780 (C84F6 #3590S; Cell Signaling),
PARP (#9542S; Cell Signaling), CDK2 (M2 sc-163; Santa Cruz), cyclin
B1 (H-433 sc-752; Santa Cruz), cyclin E1 (sc-198), mKi67
(TEC-3 M7249 DAKO), BrdU (FITC-556028; BD Pharmingen), Lamin B
(M-20 sc-6217; Santa Cruz), p21 (C-19 sc-397; Santa Cruz), PAR (4335amc-050; Trevigen), p-H2AX S129 (IF - #05-636 (Millipore), and
WB -20E3 #9718S (Cell Signaling)), p53 (Pab 240 ab26; Abcam),
53BP1 (Novus Biologicals, NB 100-304), h-RAS (C-20 sc-520; Santa
Cruz), and cyclin D1 (IP 1:50 immunoblot 1:1,000 04-221; Millipore).
siRNA and transfection
A validated pool of 4 siRNA constructs directed against the
N-terminus of the murine cyclin D1 transcript or scramble control
was purchased from Dharmacon (L-042441-00-0020 and D-00181010-20) and transfected into Ccnd1+/+ or Ccnd1KI/KI lines using
the Dharmacon 1 transfection reagent. Forty-eight hours posttransfection, cells were harvested and utilized for immunoblot,
growth, and immunofluorescence assays.
Cell growth curves
Indicated cell lines were plated in 10-cm plates in the conditions
indicated above (in biological triplicate). At the indicated time
points, cells were harvested via trypsin, washed with 1× PBS, and
resuspended in 1 ml of 1× PBS on ice. All labels were then
obscured, and live cell number was determined using trypan blue
exclusion and a hemocytometer. Blinded cell counts were then averaged and are plotted as an average of three biological replicates.
Significance was determined using a Student’s t-test.
Flow cytometry
MAF cells were challenged as described above, and adherent and
non-adherent cells were collected and fixed with 100% ice-cold
ethanol overnight. Proliferative indices were analyzed with bivariate
flow cytometry using a 1-hour pulse label of BrdU (Amersham; GE
Healthcare Life Science RPN201) before harvest, and propidium
iodide staining for cell cycle position (previously described
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Assessment of mouse in vivo cardiac function via
echocardiography
The non-invasive technique of transthoracic echocardiography was
conducted using a VisualSonics Vevo 770 high-resolution imaging
system (Gao et al, 2010). Briefly, mice were anesthetized with 1.5% of
isoflurane and two-dimensional echocardiographic views of the midventricular short axis obtained at the level of the papillary muscle tips
below the mitral valve. A minimum of 400 beats were recorded during
each study and analyzed by an independent blinded observer.
M-mode measurements of LV internal dimensions (LVID) are determined at the plane bisecting the papillary muscles according to the
American Society of Echocardiography leading edge method on 5 heart
beats chosen at random by each observer. Values of ejection fraction
and fractional shortening are obtained automatically (Gao et al, 2010).
Generation of primary cell lines and cell culture
Age-matched mice (3–4 months old) were sacrificed, washed in
70% EtOH and peritoneum harvested. Under sterile conditions,
tissue was washed 2× in 1× PBS and diced using a sterile blade.
Tissue was dissociated using collagenase (2 mg/ml in L-15 media
with DNAse) for 45 min at 37°C with gentle shaking. Tissue was
then pelleted, washed with warm 1× PBS, and further digested with
1× trypsin (0.25%) for 15 min at 37°C. The trypsin was then
neutralized with DMEM containing 10% fetal bovine serum and
plated in tissue culture grade plates. One week post-plating, tissue
was removed from the plates, and adherent cells were harvested
and re-plated. Individual cell lines were then passaged according to
a 3T3 protocol.
Xenografts
Indicated MAF cell lines were cultured as described above, then
harvested via trypsin and combined with Matrigel (BD Biosciences,
354234) at a ratio of 1:1. A total of 1 million cells were injected
subcutaneously into the flanks of nude mice (n = 10/genotype), and
tumor growth/development was measured twice weekly over a
period of 1 year. Tumor growth was monitored with electronic calipers weekly, and mice were sacrificed when tumor volume reached
750 mm3 or 3 weeks post-tumor detection. Individual tumors were
removed from mice and immediately fixed in 10% buffered formalin
overnight. Tumor sections were then processed and embedded into
paraffin blocks and cut into individual 5-lM sections. Tumor
sections were then stained with H&E or immunostained with antisera for the proliferative marker mKi67 as previously described
(Augello et al, 2014; Comstock et al, 2011, 2013). All xenograft
studies were performed in accordance with NIH and IACCUC guidelines and were approved by Thomas Jefferson University.
Cell cycle arrest
MAF lines indicated were plated at ~60% confluence in DMEM
containing 10% fetal bovine serum (FBS) and then treated with
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vehicle (DMSO 0.1%), 5 lg/ml roscovitine (G1 arrest), 1 mM
hydroxyurea (early S phase), and 2 lg/ml aphidicolin (late S
phase) for 24 h. Cells arrested in G2/M were first treated with
2 lg/ml aphidicolin for 16 h; then, cells were washed with 1× sterile PBS three times, media refreshed, and treated with 50 ng/ml of
nocodazole for 8 h. Cells were then harvested via trypsin and
lysed using RIPA buffer. Experiments were conducted in biological
triplicate.
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fixed with 3.7% formaldehyde for 10 min at room temperature and
stained with 0.01% crystal violet, and colonies greater than 50 lm
in diameter were counted. Images were taken at 400× and 200×
magnification.
b-Galactosidase staining and counts

Indicated MAF lines were plated on culture grade coverslips and
treated as described above. At the indicated time points, cells were
washed with 1× PBS, fixed with 3.7% formaldehyde for 10 min at
room temp, and stained for p-H2AX foci as previously described
(Goodwin et al, 2013). Foci were imaged on a Zeiss Confocal Laser
Scanning Microscope and counted for at least 50 cells per treatment
condition and cell line.

Individual MAF lines were plated on tissue culture grade coverslips
and treated as described above. At the indicated time points, cells
were fixed with 3.7% formaldehyde and stained for B-galactosidase
activity using a Senescence beta-Galactosidase Staining Kit (Cell
Signaling #9860S). Cells were stained at 37°C overnight and then
counterstained with the nuclear stain DAPI (Invitrogen D3571). Blue
(positive) cells were counted in three random fields for each biological replicate, along with total cell number (indicate by DAPI nuclear
staining). Data were graphed as a percent positive of total cell population and significance determined using a two-tailed Student’s
t-test.

Histology

Gene expression

Sacrifice of age-matched animals (n = at least 4 per genotype) was
conducted according to NIH guidelines and in accordance with
IACUC-approved protocols at Thomas Jefferson University. Individual organs were harvested and weighed, fixed in 10% neutral
buffered formalin, processed, and paraffin-embedded, and 5-lM
sections were stained with hematoxylin and eosin. Histopathology
and neoplastic features were determined by a board-certified veterinary pathologist.

Individual cell lines were plated in 10% FBS in DMEM and treated
as described above for 3 hours. Cells were then washed and RNA
harvested using the TRIzol method (Life Technologies 1196-018).
cDNA was generated using 1 ng of purified RNA and the SuperScript
VILO enzyme system (Life Technologies 11754-050). Expression of
Cdkn1a levels was determined using methods previously described
(Comstock et al, 2011, 2013). Primers used were as follows: Gapdh –
50 AAC TTT GGC ATT GGC AAT GTG GAA GG-30 , 50 ACA CAT TGG
GGG TAG GAA CA-30 ; and Cdkn1a – 50 - GCT GTC TTG CAC TCT
GGG GT-30 , 50 -CGT GGG CAC TTC AGG GTT TT-30 .

p-H2AX and 53BP1 foci counts

CDK4 immunoprecipitation and kinase assay
CDK4 immunoprecipitation and kinase assays were preformed as
previously described (Knudsen et al, 1998). Immunoprecipitated
CDK4 and purified human retinoblastoma protein (1.5 lg per reaction; QED Bioscience #3108) were reconstituted in 40 ll of kinase
buffer (Knudsen et al, 1998) on ice. The reaction was initiated by
the addition of ATP mix (50 lM final, 5 lCi [c-32P] ATP per reaction; Perkin Elmer) and incubated for 30 min at 30°C. Reactions
were stopped by the addition of SDS sample buffer, and samples
were rocked for 20 min at room temperature and cleared by centrifugation at 15,000 × g for 1 min. A total of 20 ll of the total reaction
was processed by SDSPAGE on a 10% polyacrylamide gel, and gels
were then fixed, stained with Coomassie blue, and dried. Rb phosphorylation was visualized by autoradiography and quantified by
Cerenkov counting of the excised band. Total counts per reaction
were determined by counting an aliquot of the radiolabeled ATP
mix to enable calculation of phosphate incorporation into Rb. Phosphate incorporation was normalized to the immunoprecipitation
efficiency of CDK4, as determined by Western blotting and densitometry, to determine the relative kinase activity.

Supplementary information for this article is available online:
http://embomolmed.embopress.org
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therapeutic resistance in multiple model systems. While the functions
of cyclin D1a which promote tumor progression have been previously
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Results
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Furthermore, cells that express cyclin D1b (under the control of the
endogenous promoter) were able to undergo transformation and
foster tumor growth, whereas cells expressing cyclin D1a were incapable of this event. Further molecular investigation uncovered novel
links between cyclin D1b expression and elevated PARP activity and
markers of genome instability, which could be exploited to effectively
inhibit tumor cell growth.
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